Cellbricks Therapeutics
Biofabrication platform for 3D-printed human tissue implants and future organ manufacturing.
About
Cellbricks Therapeutics is a Berlin-founded biotech startup focused on developing a proprietary biofabrication platform for creating vascularized human tissue implants. Their technology combines human cells with biomaterials to produce tissue constructs for implantation, initially targeting soft tissue loss, complex wounds, and reconstructive defects. The company's long-term vision is to build the capabilities for manufacturing fully functional, implantable human organs.
Key facts
At-a-glance profile data
- Headquarters
- Berlin, Germany
- Total funding
- $7M (Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 25 Mar 2026 | Seed | $7M | - |
Frequently asked
What does Cellbricks Therapeutics do?
Their platform utilizes a light-based bioprinting process that allows for high-speed production of large, viable, and vascularized tissue constructs.
How much funding has Cellbricks Therapeutics raised?
Cellbricks Therapeutics has raised a total of $7M in funding. The most recent round on record is Seed.